News >

Avelumab/Axitinib Combo Biomarker Analysis May Lend Insight to Complex RCC Landscape

Brandon Scalea
Published: Tuesday, Jun 11, 2019

Toni K. Choueiri, MD

Toni K. Choueiri, MD
A subgroup analysis of the phase III JAVELIN Renal 101 study identified molecular features that may define therapy-specific outcomes in patients with advanced renal cell carcinoma (RCC), explained Toni Choueiri, MD.

In the analysis of JAVELIN Renal 101—a trial which led to the May 2019 FDA approval of avelumab (Bavencio) plus axitinib (Inlyta) for the frontline treatment of patients with advanced RCC— researchers found that PD-L1 expression ≥1% appeared to be the greatest predictor of benefit from the PD-L1 inhibitor/VEGF TKI combination.1 This factor was associated with the longest progression-free survival (PFS) in the combination arm and the shortest PFS in patients who received sunitinib (Sutent; HR, 0.63; 95% CI, 0.49-0.81), according to findings presented at the 2019 ASCO Annual Meeting.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication